Lumitron Technologies, Inc. Creates Breakthrough Laser-Based, X-Ray Technologies

New Technology has potential to transform industrial, medical and therapeutic applications

Lumitron HyperVIEW x-ray systems are to be commercialized and manufactured in a new, state-of-the-art facility within University of California, Irvine (UCI) industrial research park

IRVINE, California, July 11, 2018 /PRNewswire/ -- Lumitron Technologies, Inc. has acquired the key licenses from the Lawrence Livermore National Laboratory that will bring to market a new generation of advanced x-ray and gamma-ray systems.

Lumitron's game-changing HyperVIEW x-ray platform is set to revolutionize many fields of human endeavor including key aspects of the medical and security industries. Unlike existing commercial endeavors which have produced x-rays in essentially the same manner for more than 120 years, Lumitron's proprietary x-ray technology represents a generational leap in scientific innovation, according to UCI's Prof. Chris Barty, Lumitron's Chief Technical Officer and former CTO of LLNL's National Ignition Facility and Photon Science Directorate, home of the world's largest laser system, the National Ignition Facility, and America's largest nuclear fusion project.

"Lumitron brings the precision and unique capabilities of billion-dollar-scale, particle-accelerator-based synchrotron x-ray light sources to the point of need in a form factor similar in size to a modern CT machine," says Prof. Barty, a world-renowned leader in the fields of laser science, x-ray and gamma-ray source development and novel photonics applications further explained. "Just as the laser has revolutionized the production and use of visible light in much of modern technology, the HyperVIEW has the potential to provide a transformational view into the human body and beyond."

"Existing clinical x-ray systems are generally limited to a resolution of just under 1mm. By contrast, the Lumitron HyperVIEW technology is capable of imaging objects up to 1000x smaller and of detection and analysis of the elemental and isotopic composition of the object. The HyperVIEW technology can also capture motion at the picosecond time-scale, that is 1000th of a billionth of a second."

According to Prof. Barty, the HyperVIEW technology presents the potential to create the first true Theranostics machine capable of both remarkable imaging detail and cellular level treatment, simultaneously. The implications for medical applications in particular are astounding.

Mr. Maurie Stang, Executive Chairman of Lumitron Technologies, Inc. said, "In today's world the acceleration of technology is unprecedented. Fields such as additive manufacturing, aerospace, security, mining, waste recycling and new composite materials sciences require non-destructive assessment and assay which can now be achieved by Lumitron's pure, Ultra-Bright Compton X-Ray source."

"In the medical field the HyperVIEW system has the potential to diagnose and treat many conditions including cancer substantially earlier and far more accurately than any current commercially available technology," he said. "The underlying, compact, high-flux, x-ray technology leverages more than USD$200 Million of research and development in advanced x-ray, laser and accelerator science that has been undertaken by the US Department of Energy at Lawrence Livermore National Laboratory and the SLAC National Accelerator Laboratory at Stanford University."

Lumitron has now established its global R&D and manufacturing facility within the industrial research park of the University of California, Irvine, home of the world-renowned Beckman Laser Institute and Medical Clinic.  It has secured interest from research-based customers from around the world and is in collaboration with some of the world's leading manufacturers of current generation x-ray systems, having received very favorable feedback about the Lumitron platform providing an important and significant step change into the future.

Lumitron's potential has attracted several high-profile members to its board of directors including Steve Sargent, previous CEO of GE Australia, and a Director of Origin Energy; Dr. Paul Rosso, past President of 3M Europe and 3M Healthcare; Dr. Ron Shnier, a world-renowned radiologist and an advisory board of leading clinicians, physicists and business people. Lumitron is targeting a NASDAQ IPO and is in discussions with leading US brokers and institutions.

About Lumitron Technologies, Inc.
Based in Irvine, California, Lumitron Technologies, Inc. was established by its executive chairman, Mr. Maurie Stang, to develop and commercialize unique x­‐ray systems that enable revolutionary new capabilities for high-fidelity imaging, ultra­-low dose imaging and hyper-precision radiotherapy.